Skip to content
10-Q

Quarterly Report

Singular Genomics Systems, Inc.

0000950170-24-125405

← back to feed
Filed
Nov 12, 2024 12:00 AM ET
Period of report
Restated figures. One or more values in this filing restate previously reported amounts.

On SEC.gov

Financials in this filing

Metric Period Value
Shares Outstanding Q3 2024 · Oct 31, 2024 2.51M sh
Shares Diluted Q3 2024 · Sep 30, 2024 2.5M sh
Shares Diluted Q3 2024 · Sep 30, 2024 2.48M sh
Shares Diluted restated Q3 2024 · Sep 30, 2023 2.42M sh
Shares Diluted restated Q3 2024 · Sep 30, 2023 2.41M sh
Stock Repurchased Q3 2024 · Sep 30, 2024 $0
Stock Repurchased Q3 2024 · Sep 30, 2023 $13K
Capex Q3 2024 · Sep 30, 2024 $33K
Capex Q3 2024 · Sep 30, 2023 $578K
Operating Cash Flow Q3 2024 · Sep 30, 2024 −$61.53M
Operating Cash Flow Q3 2024 · Sep 30, 2023 −$54.75M
Long Term Debt Q3 2024 · Sep 30, 2024 $5.17M
Long Term Debt Q3 2024 · Dec 31, 2023 $8.9M
Short Term Debt Q3 2024 · Sep 30, 2024 $5.17M
Short Term Debt Q3 2024 · Dec 31, 2023 $1.31M
Short Term Investments Q3 2024 · Sep 30, 2024 $61.21M
Short Term Investments Q3 2024 · Dec 31, 2023 $157.71M
Cash And Equivalents Q3 2024 · Sep 30, 2024 $52.62M
Cash And Equivalents Q3 2024 · Dec 31, 2023 $16.23M
Stockholders Equity Q3 2024 · Sep 30, 2024 $123.25M
Stockholders Equity Q3 2024 · Jun 30, 2024 $137.71M
Stockholders Equity Q3 2024 · Mar 31, 2024 $156.7M
Stockholders Equity Q3 2024 · Dec 31, 2023 $179.01M
Stockholders Equity Q3 2024 · Sep 30, 2023 $199.03M
Stockholders Equity Q3 2024 · Jun 30, 2023 $218.39M
Stockholders Equity Q3 2024 · Mar 31, 2023 $240.33M
Stockholders Equity Q3 2024 · Dec 31, 2022 $260.32M
Current Liabilities Q3 2024 · Sep 30, 2024 $17.61M
Current Liabilities Q3 2024 · Dec 31, 2023 $18.29M
Total Liabilities Q3 2024 · Sep 30, 2024 $63.3M
Total Liabilities Q3 2024 · Dec 31, 2023 $86.46M
Current Assets Q3 2024 · Sep 30, 2024 $129.81M
Current Assets Q3 2024 · Dec 31, 2023 $192.23M
Total Assets Q3 2024 · Sep 30, 2024 $186.55M
Total Assets Q3 2024 · Dec 31, 2023 $265.47M
Eps Diluted Q3 2024 · Sep 30, 2024 −$6.72
Eps Diluted Q3 2024 · Sep 30, 2024 −$25.41
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$9.25
Eps Diluted restated Q3 2024 · Sep 30, 2023 −$29.73
Eps Basic Q3 2024 · Sep 30, 2024 −$6.72
Eps Basic Q3 2024 · Sep 30, 2024 −$25.41
Eps Basic restated Q3 2024 · Sep 30, 2023 −$9.25
Eps Basic restated Q3 2024 · Sep 30, 2023 −$29.73
Sga Expense Q3 2024 · Sep 30, 2024 $8.2M
Sga Expense Q3 2024 · Sep 30, 2024 $35.04M
Sga Expense Q3 2024 · Sep 30, 2023 $13.25M
Sga Expense Q3 2024 · Sep 30, 2023 $41.35M
Rd Expense Q3 2024 · Sep 30, 2024 $9.57M
Rd Expense Q3 2024 · Sep 30, 2024 $31.79M
Rd Expense Q3 2024 · Sep 30, 2023 $11.22M
Rd Expense Q3 2024 · Sep 30, 2023 $36.07M
Net Income Q3 2024 · Sep 30, 2024 −$16.8M
Net Income Q3 2024 · Sep 30, 2024 −$63.07M
Net Income Q3 2024 · Jun 30, 2024 −$21.25M
Net Income Q3 2024 · Mar 31, 2024 −$25.02M
Net Income Q3 2024 · Sep 30, 2023 −$22.36M
Net Income Q3 2024 · Sep 30, 2023 −$71.57M
Net Income Q3 2024 · Jun 30, 2023 −$25.58M
Net Income Q3 2024 · Mar 31, 2023 −$23.63M
Operating Income Q3 2024 · Sep 30, 2024 −$18.07M
Operating Income Q3 2024 · Sep 30, 2024 −$67.72M
Operating Income Q3 2024 · Sep 30, 2023 −$24.54M
Operating Income Q3 2024 · Sep 30, 2023 −$77.52M
Gross Profit Q3 2024 · Sep 30, 2024 −$301K
Gross Profit Q3 2024 · Sep 30, 2024 −$897K
Gross Profit Q3 2024 · Sep 30, 2023 −$65K
Gross Profit Q3 2024 · Sep 30, 2023 −$101K
Cost Of Revenue Q3 2024 · Sep 30, 2024 $707K
Cost Of Revenue Q3 2024 · Sep 30, 2024 $2.48M
Cost Of Revenue Q3 2024 · Sep 30, 2023 $527K
Cost Of Revenue Q3 2024 · Sep 30, 2023 $1.93M
Revenue Q3 2024 · Sep 30, 2024 $406K
Revenue Q3 2024 · Sep 30, 2024 $1.59M
Revenue Q3 2024 · Sep 30, 2023 $462K
Revenue Q3 2024 · Sep 30, 2023 $1.83M